(RTTNews) - Dogged by patent expirations, regulatory setbacks and high-profile drug trial failures, 2008 has been a whirlwind year for Pfizer. The drug titan is seeking to cure its ills with serious retrenching measures and by shifting its research ...
Read more...
We’ve been straining to see inside our congressional crystal ball for hints on what Henry Waxman’s win in the contest for chairman of the powerful House Energy and Commerce Committee means for the drug and device industries. The soon-to-be ex ...
Read more...
MONDAY, Nov. 3 (HealthDay News) -- The increased risk of heart attack that comes with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) to treat arthritis pain is directly related to the specific pain-causing molecule they act against, a new ...
Read more...
TRENTON, New Jersey : A doubled risk of heart attack, stroke and death persisted at least a year after people stopped taking withdrawn painkiller Vioxx, according to an analysis of long-term data from the study that led drugmaker Merck & Co. to stop ...
Read more...
CHICAGO (Reuters) - A long-term analysis of people who took the arthritis drug Vioxx confirms it doubles the risk of strokes and heart attacks, researchers said on Monday, but this risk goes away a year after people stop taking it. And other drugs in ...
Read more...
TRENTON, N.J. - Drug giant Pfizer Inc. has reached an $894 million deal to settle the bulk of the lawsuits over its withdrawn pain reliever Bextra, following the lead of rival Merck & Co., which is spending five times as much to settle Vioxx suits ...
Read more...
Pfizer Inc. (PFE) agreed to pay $894 million to settle the bulk of litigation and state government probes surrounding its pain drugs Celebrex and Bextra, which were linked to increased risk for heart attacks and strokes. The New York drug maker said ...
Read more...